<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thyroid hormone suppressive therapy for thyroid nodules and benign goiter
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thyroid hormone suppressive therapy for thyroid nodules and benign goiter
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thyroid hormone suppressive therapy for thyroid nodules and benign goiter
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of thyroid hormone suppressive therapy in euthyroid patients with solitary benign thyroid nodules or sporadic nontoxic multinodular goiters is controversial. Most studies have shown that few thyroid nodules regress in patients taking thyroid hormone. However, suppressive therapy does appear to interfere with goitrogenesis in many patients, and it has been proposed that it could reduce the risk of thyroid oncogenesis, as well. A 2016 survey of members of the American College of Physicians, American Academy of Family Practice, and the Endocrine Society found that 24.5 percent of respondents used thyroid hormone suppressive therapy, including 14 percent of endocrinologists [
         <a href="#rid1">
          1
         </a>
         ]. It is therefore important to review the evidence.
        </p>
        <p>
         This topic will review potential benefits of thyroid hormone suppressive therapy in patients with benign nodules or goiter. The risks of thyroid hormone suppressive therapy, the overall approach to the evaluation and treatment of patients with goiter and with thyroid nodules, as well as the use of thyroid hormone suppressive therapy in thyroid cancer are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">
          "Subclinical hyperthyroidism in nonpregnant adults", section on 'Potential consequences of subclinical hyperthyroidism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7835.html" rel="external">
          "Clinical presentation and evaluation of goiter in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">
          "Diagnostic approach to and treatment of thyroid nodules"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Suppression of thyroid-stimulating hormone (TSH) secretion in normal subjects by the administration of thyroid hormone results in thyroid atrophy [
         <a href="#rid2">
          2
         </a>
         ]. Although the pathogenesis of thyroid nodules and sporadic nontoxic multinodular goiters is poorly understood, TSH is presumed to be necessary if not sufficient, and therefore, suppression of TSH secretion might be expected to result in a decrease in nodule or goiter size or at least prevent further enlargement.
        </p>
        <p>
         The importance of TSH in goiter formation varies with the cause of the goiter. For example, in patients with iodine deficiency or chronic autoimmune (Hashimoto's) thyroiditis, an increase in TSH secretion is the predominant cause of goiter. In contrast, most patients with thyroid nodules or sporadic nontoxic multinodular goiters have normal serum TSH concentrations. In them, particularly those with nontoxic multinodular goiters, the thyroid enlargement is probably caused by several growth factors (including TSH) that act over time on thyroid follicular cells that have different synthetic and growth potentials. The result is diffuse and later multinodular thyroid enlargement; some nodules eventually become autonomous [
         <a href="#rid3">
          3
         </a>
         ], and others may undergo cystic degeneration.
        </p>
        <p>
         Because thyroid hormone is presumed to reduce goiter size by reducing TSH secretion, suppressive therapy would be expected to be
         <strong>
          ineffective
         </strong>
         in patients in whom serum TSH concentrations were already subnormal due to autonomous thyroid hormone production.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          NONTOXIC GOITER
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of a history of childhood head and neck irradiation, we do not routinely treat euthyroid goitrous patients from areas of iodine sufficiency with
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         (T4). The American Thyroid Association (ATA) also does not recommend suppression therapy of benign thyroid nodules in iodine-sufficient populations owing to concern that the risks of suppressive therapy, especially in older patients, outweigh its benefits [
         <a href="#rid4">
          4
         </a>
         ]. T4 suppressive therapy was previously commonly used for goiter, but its use has declined since the 1990s primarily due to concerns regarding the long-term side effects from the induction of subclinical or overt hyperthyroidism, such as reduced bone density and increased risk of atrial fibrillation. (See
         <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">
          "Subclinical hyperthyroidism in nonpregnant adults"
         </a>
         .)
        </p>
        <p>
         However, in iodine-deficient patients or selected younger patients who are concerned about growth of their goiter, a trial of T4 aiming either for minimal TSH suppression or a low-normal TSH is a reasonable intervention pending further studies, especially those that assess the efficacy of suppressing serum TSH into the low-normal range. (See
         <a class="local">
          'TSH goal'
         </a>
         below.)
        </p>
        <p>
         Thyroid hormone suppressive therapy is effective in reducing goiter volume and preventing the development of new nodules in some patients, particularly in patients from regions of the world with borderline or low iodine intake [
         <a href="#rid5">
          5-7
         </a>
         ]. (See
         <a class="local">
          'Efficacy'
         </a>
         below.)
        </p>
        <p>
         The evaluation and management of nontoxic goiter is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7835.html" rel="external">
          "Clinical presentation and evaluation of goiter in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1785826">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In randomized control trials, thyroid hormone (thyroxine; T4) suppression can interfere with the process of goitrogenesis (goiter growth and new nodule formation). Only some goiters respond, while others grow despite T4 treatment [
         <a href="#rid5">
          5,8
         </a>
         ]. Treatment must be continued or goitrogenesis resumes [
         <a href="#rid5">
          5
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a double-blind trial, 78 patients with nontoxic goiter (average thyroid volume 53 mL) were randomly assigned T4 or placebo for nine months and then followed for an additional nine months [
         <a href="#rid5">
          5
         </a>
         ]. Thyroid volume, as assessed by ultrasonography, decreased in a greater proportion of patients in the T4 group (58 versus 5 percent)  (
         <a class="graphic graphic_figure graphicRef54294" href="/z/d/graphic/54294.html" rel="external">
          figure 1
         </a>
         ). In the responders, the mean decrease in thyroid volume was 25 percent. Over half the patients in the T4 group developed thyrotoxic symptoms during the trial, and goiter growth resumed in this group after therapy was discontinued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another trial from an iodine-deficient region of Italy, 71 premenopausal women with benign, nontoxic, multinodular thyroid disease (mean thyroid volume 15 mL) were randomly assigned T4 (2 mcg/kg) or no treatment [
         <a href="#rid6">
          6
         </a>
         ]. Compared with baseline values, treatment with T4 for one year significantly reduced mean thyroid volume (15.6 to 10.6 mL), mean dominant nodule volume (1.8 to 0.8 mL), and the number of nodules greater than 5 mm (0.8 to 0.4). In contrast, those parameters significantly increased from baseline in controls (14.8 to 20.0 mL, 1.2 to 2.5 mL, and 0.7 to 1.5, respectively).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1785833">
         <span class="h2">
          TSH goal
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is possible that the benefits of T4 therapy do not require suppression to subnormal serum TSH concentrations. In one trial, 49 patients from Istanbul (a city with reported adequate iodine intake) with solitary thyroid nodules were randomly assigned to receive high-dose (serum TSH &lt;0.01 mU/L) or low-dose (serum TSH 0.4 to 0.6 mU/L) T4 therapy [
         <a href="#rid9">
          9
         </a>
         ]. High- and low-dose T4 therapy were equally effective in reducing nodule volume (36 and 45 percent reduction in nodule size in the high- and low-dose groups, respectively).
        </p>
        <p>
         In another trial of T4 therapy, 1024 patients with mild to moderate iodine deficiency and one or more thyroid nodules were randomly assigned to T4 (goal TSH 0.2 to 0.8 mU/L), iodine (150 mcg, ie, the amount of iodine present in most multivitamins in the United States), T4 plus iodine, or placebo [
         <a href="#rid7">
          7
         </a>
         ]. After one year, mean thyroid nodule volume decreased in all groups (-12.1, -9.0, -21.6, and -5.2 percent, respectively). Treatment with T4 plus iodine was significantly superior to placebo, T4, and iodine alone. Individual changes in thyroid nodule volume were variable. Decreases of more than 50 percent were seen in 7.6, 9.5, 11.3, and 8.5 percent of the nodules in the T4, iodine, T4 plus iodine, and placebo groups, respectively [
         <a href="#rid7">
          7
         </a>
         ]. Thus, maintaining TSH in the lower end of or just below the normal range (rather than below 0.01 mU/L) appears to be efficacious. It is possible that this strategy will mitigate the adverse effects of T4 suppressive therapy. This concept requires further study.
        </p>
        <p class="headingAnchor" id="H1785840">
         <span class="h2">
          Special populations
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Irradiated patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         External radiation exposure during childhood (therapeutic radiation as part of cancer therapy, radiation for nonmalignant conditions, exposure from nuclear power plants [Chernobyl, Fukushima]) increases thyroid tumorigenesis. There are few data to determine the efficacy of thyroid hormone suppressive therapy in reducing nodular thyroid growth in this population [
         <a href="#rid10">
          10,11
         </a>
         ]. In a nonrandomized study of 632 adults who were treated prior to age 16 with conventional radiation for nonmalignant conditions and who subsequently had benign thyroid nodules removed surgically, patients who were treated with thyroid hormone had a lower incidence of recurrent nodules than those who were not (14 versus 34 percent; relative risk [RR] 0.69, 95% CI 0.47-1.01) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7059.html" rel="external">
          "Radiation-induced thyroid disease"
         </a>
         .)
        </p>
        <p>
         External radiation exposure for malignancy during childhood also increases the risk of hypothyroidism [
         <a href="#rid13">
          13,14
         </a>
         ]. All patients with hypothyroidism require treatment with T4 (see
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         ). However, whether irradiated euthyroid patients with one or more thyroid nodules or multinodular goiter benefit from T4 suppressive therapy is uncertain. In the absence of contraindications (such as atrial arrhythmia, ischemic heart disease, or osteoporosis), some UpToDate experts treat euthyroid patients with benign thyroid nodules and a history of external radiation exposure in childhood, aiming for a low-normal or minimally subnormal serum TSH concentration. Other experts, however, would not treat such euthyroid patients, unless the serum TSH was in the upper part of the normal range (ie, &gt;3.0 mU/L).
        </p>
        <p class="headingAnchor" id="H1785743">
         <span class="h3">
          Suppressive therapy after surgery for nontoxic goiter
         </span>
         <span class="headingEndMark">
          —
         </span>
         The apparent efficacy of thyroid hormone therapy for suppression of nontoxic goiter led to its use to prevent goiter recurrence after partial thyroidectomy [
         <a href="#rid15">
          15-17
         </a>
         ]. Two randomized trials showed a trend toward fewer recurrences with T4 therapy (15 versus 22 percent and 21 versus 35 percent) that were not statistically significant [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Hashimoto's thyroiditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid hormone is particularly efficacious in reducing goiter size when thyroid enlargement is due to an elevated serum TSH concentration in patients with hypothyroidism due to Hashimoto's thyroiditis. However, even euthyroid goitrous patients with Hashimoto's thyroiditis may respond to suppressive therapy with T4 [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11800002">
         <span class="h2">
          Oncogenesis in goiter
         </span>
         <span class="headingEndMark">
          —
         </span>
         A potential benefit of T4 suppressive therapy is a reduction in the risk of thyroid cancer. The risk of thyroid cancer in patients with thyroid nodules increases with increasing serum TSH concentrations [
         <a href="#rid21">
          21
         </a>
         ]. In a retrospective analysis of patients with nodular goiter, the prevalence of papillary thyroid cancer was significantly reduced in 7859 patients with nodular goiter taking T4 compared with 20,055 patients not taking T4 (3.2 versus 5.1 percent) [
         <a href="#rid22">
          22
         </a>
         ]. These data suggest that suppressive therapy might reduce oncogenesis in goiter [
         <a href="#rid22">
          22
         </a>
         ]. This hypothesis is still speculative, and additional data are required. The use of T4 suppression therapy to reduce tumor growth and recurrence in patients with differentiated thyroid cancer is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          SOLITARY NODULES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid hormone suppressive therapy is effective in reducing nodule volume and preventing the development of new nodules in some patients, particularly those patients from regions of the world with borderline or low iodine intake. In iodine-sufficient regions, only 17 to 25 percent of patients with a solitary nodule will have a decrease in nodule size (more than 50 percent) as a result of T4 treatment [
         <a href="#rid8">
          8,23-25
         </a>
         ]. Furthermore, in some patients, solitary nodules regress spontaneously.
        </p>
        <p>
         In view of the small percentage of thyroid nodules that regress after T4 treatment, the modest responses, and the potential adverse risks (atrial arrhythmias and reduced bone density) of thyroid hormone suppressive therapy, we do not suggest the routine use of thyroid hormone suppressive therapy for solitary palpable thyroid nodules in areas of iodine sufficiency. This is consistent with American Thyroid Association (ATA) guidelines [
         <a href="#rid26">
          26
         </a>
         ]. However, in iodine-deficient regions, a trial of T4 aiming for low-normal or minimally subnormal TSH concentrations appears to be a reasonable intervention, pending further studies that assess the efficacy of suppressing serum TSH into the low normal range [
         <a href="#rid9">
          9,27
         </a>
         ]. (See
         <a class="local">
          'TSH goal'
         </a>
         above.)
        </p>
        <p>
         Data on the impact of thyroid hormone suppressive therapy for solitary nodules are conflicting, as illustrated by the results of several randomized trials [
         <a href="#rid8">
          8,9,23,28-36
         </a>
         ] and the following meta-analyses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of six trials (346 patients) showed that patients randomly assigned to suppressive thyroid hormone therapy for longer than six months were more likely to have a reduction in nodule volume by more than 50 percent, but this was not statistically significant (relative risk [RR] 1.90, 95% CI 0.95-3.81) [
         <a href="#rid24">
          24
         </a>
         ]. The meta-analysis was limited by heterogeneity in the study results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of nine trials (609 patients) concluded that thyroid hormone suppression was more likely than placebo or no treatment to reduce nodule volume &gt;50 percent (response rate 22 versus 10 percent; RR 1.88, 95% CI 1.18-3.01) [
         <a href="#rid37">
          37
         </a>
         ]. However, long-term treatment appeared to be less effective, and regrowth was likely after cessation of thyroid hormone.
        </p>
        <p>
        </p>
        <p>
         The trials included in the meta-analyses enrolled patients with solitary thyroid nodules and ultrasonographic evaluation of nodule volume. Appropriate suppression of TSH was documented by measurement of serum TSH or by thyrotropin-releasing hormone (TRH) stimulation test.
        </p>
        <p>
         In one of the trials in the meta-analysis, 49 patients with solitary thyroid nodules were randomly assigned to receive high-dose (serum TSH &lt;0.01 mU/L) or low-dose (serum TSH 0.4 to 0.6 mU/L) T4 therapy [
         <a href="#rid9">
          9
         </a>
         ]. High- and low-dose T4 therapy were equally effective in reducing nodule volume (36 and 45 percent reduction in nodule size in the high- and low-dose groups, respectively). The term "
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         nonsuppressive therapy" was suggested to describe the effects of levothyroxine on thyroid nodule growth when the goal is to reduce TSH into the low-normal range [
         <a href="#rid27">
          27
         </a>
         ]. In one nonrandomized trial from Italy, administering levothyroxine in a dose that achieved a TSH of 0.5 to 0.8 mU/L resulted in a slower rate of nodule growth, with significant differences between levothyroxine-treated and untreated patients after four years [
         <a href="#rid27">
          27
         </a>
         ]. The potential benefits and side effects of this approach require further investigation.
        </p>
        <p>
         The majority of the trials in the meta-analyses were of relatively short duration (6 to 18 months) [
         <a href="#rid23">
          23,24,37
         </a>
         ]. In one of the trials with longer follow-up, a five-year trial from an iodine-sufficient area of Italy in which 83 patients were randomly assigned to receive T4 or no treatment, nodule volume (measured by ultrasonography) decreased in only a small subset of T4-treated patients (those with complete TSH suppression) [
         <a href="#rid36">
          36
         </a>
         ]. After five years, however, fewer patients receiving T4 suppressive therapy developed new sonographically detected nodules (7.5 versus 28.5 percent).
        </p>
        <p>
         In another of the trials included in the meta-analyses, the characteristics of patients with nodules more likely to respond to suppressive therapy were [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abundant colloid on biopsy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Degenerative changes if the nodules were small (&lt;2.4 mL in volume or &lt;1.7 cm in diameter)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of hyperplastic or fibrotic changes
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H387545458">
         <span class="h2">
          Oncogenesis in follicular neoplasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of thyroid cancer in patients with thyroid nodules increases with increasing serum TSH concentrations [
         <a href="#rid21">
          21
         </a>
         ]. Treatment with T4 therapy in a dose adjusted to reduce TSH into the low-normal range (
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         nonsuppressive therapy) may reduce the risk of thyroid cancer. As an example, in a preliminary retrospective report of levothyroxine nonsuppressive therapy in 532 patients undergoing surgery for indeterminate thyroid nodules (Bethesda III or Bethesda IV cytology), there was a lower rate of malignancy in Bethesda IV nodules (suspicious for a follicular neoplasm) in patients who were taking nonsuppressive doses of levothyroxine for at least two years to reduce nodule growth [
         <a href="#rid38">
          38
         </a>
         ]. Exclusion criteria included thyroid autoimmunity, nodules &gt;4 cm, thyroid malignancy elsewhere in the gland, radiation exposure or treatment, and a positive family history of cancer. Unfortunately, nodule size was not reported in this study. Since capsular and vascular invasion (the markers of a follicular cancer) is positively associated with size in follicular neoplasms and levothyroxine may reduce growth of thyroid nodules even when TSH is in the normal range ("levothyroxine nonsuppressive therapy"), these preliminary data suggest a reduction in oncogenesis with levothyroxine. (See
         <a class="local">
          'Oncogenesis in goiter'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H14735925">
         <span class="h1">
          SUGGESTED APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncertainty and controversy remain regarding the efficacy, risks, and benefits of thyroid hormone suppressive therapy for thyroid nodules and benign goiter. Because T4-suppressive therapy results (by definition) in subclinical hyperthyroidism, treated patients are at increased risk for atrial fibrillation, other cardiac abnormalities, or reduced bone density. The use of T4 suppression has, therefore, dramatically declined. Since 1996, the American Thyroid Association (ATA) guidelines have
         <strong>
          not
         </strong>
         recommended thyroid hormone suppressive therapy for benign thyroid nodules and nodular goiter in iodine sufficient populations. (See
         <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">
          "Subclinical hyperthyroidism in nonpregnant adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7882.html" rel="external">
          "Bone disease with hyperthyroidism and thyroid hormone therapy"
         </a>
         .)
        </p>
        <p>
         Since only 17 to 25 percent of nodules regress and the degree of regression is modest, we do not suggest T4 suppression for solitary or dominant thyroid nodules. We do not routinely use T4 suppression for patients with nodular goiter. However, in select patients (history of external radiation exposure during childhood, iodine-deficient region, and younger patients with growing diffuse or nodular goiter who are concerned about growth of their goiter), a trial of T4 aiming either for minimal TSH suppression or a low-normal TSH is a reasonable intervention, pending further studies, especially those that assess the efficacy of suppressing serum TSH into the low-normal range, which would mitigate the adverse effects of treatment.
        </p>
        <p>
         Speculation that suppressive therapy may reduce the risk of oncogenesis as well as goitrogenesis may result in reconsideration of T4 suppression for more patients with goiter, especially if efficacy can be demonstrated when TSH is suppressed into the low-normal range. Suppressive therapy is not useful if the TSH is already subnormal.
        </p>
        <p class="headingAnchor" id="H1971774020">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113808.html" rel="external">
          "Society guideline links: Thyroid nodules and cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14736271">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15901.html" rel="external">
          "Patient education: Thyroid nodules (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15437.html" rel="external">
          "Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2162.html" rel="external">
          "Patient education: Thyroid nodules (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2178.html" rel="external">
          "Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2168.html" rel="external">
          "Patient education: Antithyroid drugs (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14736348">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroxine (T4) suppression interferes with goitrogenesis (goiter growth and new nodule formation). Only some goiters respond, while others grow despite T4 treatment. Treatment must be continued or goitrogenesis resumes. (See
         <a class="local">
          'Nontoxic goiter'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T4 suppression may also interfere with oncogenesis in nodular goiter. (See
         <a class="local">
          'Oncogenesis in goiter'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In iodine-sufficient regions, 17 to 25 percent of patients with a solitary (or dominant) thyroid nodule will have a modest decrease in nodule size (&gt;50 percent) as a result of T4 suppression therapy. In some patients, solitary nodules regress spontaneously. (See
         <a class="local">
          'Solitary nodules'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because T4-suppressive therapy results (by definition) in subclinical hyperthyroidism, treated patients are at increased risk for atrial fibrillation, other cardiac abnormalities, and/or reduced bone density. The American Thyroid Association (ATA) guidelines recommend against T4-suppressive therapy because the risks outweigh the advantages. (See
         <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">
          "Subclinical hyperthyroidism in nonpregnant adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7882.html" rel="external">
          "Bone disease with hyperthyroidism and thyroid hormone therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most euthyroid patients with diffuse or nodular goiter, we suggest not routinely treating with T4 suppression therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, in selected patients (iodine deficient, history of childhood neck radiation, younger patients with growing diffuse or nodular goiter who are concerned about growth of their goiter), a trial of T4 aiming either for minimal thyroid-stimulating hormone (TSH) suppression or a low-normal TSH is a reasonable intervention. Suppressive therapy is not useful if the TSH is already subnormal. (See
         <a class="local">
          'Suggested approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For euthyroid patients with solitary nodules living in iodine-sufficient regions of the world, we suggest not treating with T4 suppressive therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, in iodine-deficient regions, a trial of T4 aiming for low-normal or minimally subnormal TSH concentrations may be a reasonable alternative. (See
         <a class="local">
          'Solitary nodules'
         </a>
         above and
         <a class="local">
          'Suggested approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of thyroid hormone suppressive therapy for prevention of recurrence in patients with differentiated thyroid cancer is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Papaleontiou M, Haymart MR. INAPPROPRIATE USE OF SUPPRESSIVE DOSES OF THYROID HORMONE IN THYROID NODULE MANAGEMENT: RESULTS FROM A NATIONWIDE SURVEY. Endocr Pract 2016; 22:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rienhoff, WF Jr. Microscopic changes induced in thyroid gland by oral administration of desiccated thyroid. Arch Surg 1940; 41:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Studer H, Peter HJ, Gerber H. Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. Endocr Rev 1989; 10:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990; 336:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cesareo R, Iozzino M, Isgrò MA, et al. Short term effects of levothyroxine treatment in thyroid multinodular disease. Endocr J 2010; 57:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grussendorf M, Reiners C, Paschke R, et al. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2011; 96:2786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wémeau JL, Caron P, Schvartz C, et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 2002; 87:4928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koc M, Ersoz HO, Akpinar I, et al. Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial. Clin Endocrinol (Oxf) 2002; 57:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy ED, Scanlon EF, Garces RM, et al. Thyroid hormone administration in irradiated patients. J Surg Oncol 1986; 31:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeGroot LJ. Radiation and thyroid disease. Baillieres Clin Endocrinol Metab 1988; 2:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbiah S, Collins BJ, Schneider AB. Factors related to the recurrence of thyroid nodules after surgery for benign radiation-related nodules. Thyroid 2007; 17:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow EJ, Friedman DL, Stovall M, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2009; 53:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85:3227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BERGFELT G, RISHOLM L. POSTOPERATIVE THYROID HORMONE THERAPY IN NONTOXIC GOITRE. Acta Chir Scand 1963; 126:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson PE, Hurley PR, Rosswick P. Conservative treatment and long term prophylactic thyroxine in the prevention of recurrence of multinodular goiter. Surg Gynecol Obstet 1990; 171:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellantone R, Lombardi CP, Boscherini M, et al. Predictive factors for recurrence after thyroid lobectomy for unilateral non-toxic goiter in an endemic area: results of a multivariate analysis. Surgery 2004; 136:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bistrup C, Nielsen JD, Gregersen G, Franch P. Preventive effect of levothyroxine in patients operated for non-toxic goitre: a randomized trial of one hundred patients with nine years follow-up. Clin Endocrinol (Oxf) 1994; 40:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hegedüs L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab 1999; 84:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svensson J, Ericsson UB, Nilsson P, et al. Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis. J Clin Endocrinol Metab 2006; 91:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012; 97:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiore E, Rago T, Provenzale MA, et al. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocr Relat Cancer 2010; 17:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998; 83:3881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002; 87:4154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998; 128:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puzziello A, Carrano M, Angrisani E, et al. Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy. J Endocrinol Invest 2014; 37:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gharib H, James EM, Charboneau JW, et al. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 1987; 317:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mainini E, Martinelli I, Morandi G, et al. Levothyroxine suppressive therapy for solitary thyroid nodule. J Endocrinol Invest 1995; 18:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lima N, Knobel M, Cavaliere H, et al. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 1997; 7:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung PS, Lee JM, Boey JH. Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study. World J Surg 1989; 13:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reverter JL, Lucas A, Salinas I, et al. Suppressive therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol (Oxf) 1992; 36:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larijani B, Pajouhi M, Bastanhagh MH, et al. Evaluation of suppressive therapy for cold thyroid nodules with levothyroxine: double-blind placebo-controlled clinical trial. Endocr Pract 1999; 5:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Rosa GL, Lupo L, Giuffrida D, et al. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med 1995; 122:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Rosa GL, Ippolito AM, Lupo L, et al. Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. J Clin Endocrinol Metab 1996; 81:4385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papini E, Petrucci L, Guglielmi R, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 1998; 83:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sdano MT, Falciglia M, Welge JA, Steward DL. Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. Otolaryngol Head Neck Surg 2005; 133:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaliszewski K, Diakowska D, Wojtczak B, et al. Patients with III and IV category of the Bethesda System under levothyroxine non-suppressive therapy have a lower rate of thyroid malignancy. Sci Rep 2019; 9:8409.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7887 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27893292" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : INAPPROPRIATE USE OF SUPPRESSIVE DOSES OF THYROID HORMONE IN THYROID NODULE MANAGEMENT: RESULTS FROM A NATIONWIDE SURVEY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Microscopic changes induced in thyroid gland by oral administration of desiccated thyroid
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2666115" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973768" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20683172" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Short term effects of levothyroxine treatment in thyroid multinodular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715542" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12414852" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12390336" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3724174" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Thyroid hormone administration in irradiated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3066329" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Radiation and thyroid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17274748" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Factors related to the recurrence of thyroid nodules after surgery for benign radiation-related nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19459201" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10999813" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14085166" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : POSTOPERATIVE THYROID HORMONE THERAPY IN NONTOXIC GOITRE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2120782" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Conservative treatment and long term prophylactic thyroxine in the prevention of recurrence of multinodular goiter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15657583" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Predictive factors for recurrence after thyroid lobectomy for unilateral non-toxic goiter in an endemic area: results of a multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8187295" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Preventive effect of levothyroxine in patients operated for non-toxic goitre: a randomized trial of one hundred patients with nine years follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10022449" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16507633" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22278420" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20167722" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9814462" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12213864" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9490600" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Thyroxine suppressive therapy in patients with nodular thyroid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19860577" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25008459" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3295553" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8787957" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Levothyroxine suppressive therapy for solitary thyroid nodule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9349571" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2696232" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1559296" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Suppressive therapy with levothyroxine for solitary thyroid nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251662" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Evaluation of suppressive therapy for cold thyroid nodules with levothyroxine: double-blind placebo-controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7985890" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8954046" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506726" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143188" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31182752" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Patients with III and IV category of the Bethesda System under levothyroxine non-suppressive therapy have a lower rate of thyroid malignancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
